Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6606 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2024-10-28 (pharmaphorum.com)
Biogen shows its IgAN hand with felzartamab data
The main asset in Biogen's $1.8bn takeover of HI-Bio, anti-CD38 drug felzartamab, delivers a positive phase 2 readout in rare disease IgAN.
Read more
2024-10-24 (saudeonline.pt)
Biogen presents data on spinal muscular atrophy
The DEVOTE findings support the clinical benefits of a high-dose regimen (50/28 mg) of spinal muscular atrophy treatment.
Read more
2024-10-04 (law.com)
Lawsuit Alleging $23 Million Contract Breach Against Biogen Moves Forward
Acting Manhattan Supreme Court Justice Anar Rathod Patel last week denied a motion to dismiss from defendants Reata and Biogen, finding that fact questions remained.
Read more
2024-09-25 (tradingsat.com)
Biogen idec: Well oriented after data in lupus
(CercleFinance.com) - UCB climbs 3% in Brussels after the announcement, with its partner Biogen, of the first positive results of the phase 3 study...
Read more
2024-09-25 (tradingsat.com)
Biogen idec: Positive phase III data in lupus
(CercleFinance.com) - UCB and Biogen announce initial positive results from the PHOENYCS GO phase 3 study evaluating their dapirolizumab pegol, in…
Read more
2024-09-18 (hitnews.co.kr)
Alzheimer's treatment Lechembe: A case of long-term medication
The FDA officially approved Leqembi (Lecanemab), an Alzheimer's disease treatment jointly developed by Biogen and Esai, on July 6, 2023. Rechemvi is a humanized monoclonal antibody drug targeting beta-amyloid (Aβ) and is an improved form of Adduhelm, which was first approved by two companies for the same target. Now that lecanemab has been in clinical use in the U.S. for just over a year, doctors are asking how long they should continue to be treated with the antibody. But the answer is unknown. Eisai has filed a ‘supplemental biological authorization application’ with the FDA.
Read more
2024-08-20 (citeline.com)
Biogen Accused Of ‘Paying’ PBMs To ‘Manipulate’ US Generic Tecfidera Market
Spooked by the prospect of earlier-than-expected US generic competition to its powerhouse MS brand Tecfidera, Biogen entered into illicit agreements with PBMs to stifle generic competition while it “scrambled” to switch the market to its follow-on brand, a US class action lawsuit alleges.
Read more
2024-06-08 (deraktionaer.de)
Biogen stock
Current prices, master data, charts and further information on the Biogen security (ISIN: US09062X1037, WKN: 789617)
Read more
2024-05-20 (concurrences.com)
The Italian Competition Authority launches an investigation into suspected pay-for-delay agreements between eight pharma companies concerning a biosimilar drug (Biogen / Samsung / Genentech...)
On May 21, 2024, the Italian Competition Authority (the AGCM or ICA) opened new proceedings against eight pharmaceutical companies to investigate suspected pay-for-delay practices in breach of the…
Read more
2024-02-05 (biospace.com)
5 Alzheimer’s Data Readouts to Watch in 2024 | BioSpace
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.
Read more
2024-01-12 (pr-neuigkeiten.de)
Jackery continues the partnership with the WWF
Identity theft when buying a car – keep an eye out for fraudsters Identity theft when buying a car – keep an eye out
Read more
2023-06-15 (statnews.com)
Biogen's messy board, Laronde's data problem, & the downside of a boom
Can unicorns survive without data? Did biotech get over its skis? And what is going on at Biogen? All that and more on the new episode of "The Readout LOUD."
Read more